U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22FN3O3.ClH
Molecular Weight 395.856
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GREPAFLOXACIN HYDROCHLORIDE

SMILES

Cl.CC1CN(CCN1)C2=C(F)C(C)=C3C(=O)C(=CN(C4CC4)C3=C2)C(O)=O

InChI

InChIKey=IEPMBYOIQGCVHO-UHFFFAOYSA-N
InChI=1S/C19H22FN3O3.ClH/c1-10-8-22(6-5-21-10)15-7-14-16(11(2)17(15)20)18(24)13(19(25)26)9-23(14)12-3-4-12;/h7,9-10,12,21H,3-6,8H2,1-2H3,(H,25,26);1H

HIDE SMILES / InChI

Molecular Formula C19H22FN3O3
Molecular Weight 359.3947
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20-695_Raxar_Pharma.pdf | https://www.drugbank.ca/drugs/DB00365

Grepafloxacin is a monofluorinated quinolone with a cyclopropyl group at position 1, a 3-methyl-1piperazinyl group at position 7 and a methyl substitution at the 5 position, that was synthesized by Otsuka in Japan. It exhibited in vitro activity against a wide variety of both Gram-positive and Gram-negative bacteria including anaerobic species. The compound was reported to have a broad spectrum of activity, particularly against pathogens responsible for community-acquired respiratory infections including those caused by beta-lactam and macrolide-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Japanese researchers also reported that unlike other quinolones, grepafloxacin reached high levels in the bile and might also be useful in the treatment of biliary tract infection. Grepafloxacin was administered once daily and did not require dosage adjustment for renal insufficiency, but grepafloxacin tablets were contraindicated in patients with hepatic failure. Otsuka Pharmaceutical signed a licensing agreement for grepafloxacin with GlaxoSmithKline. According to this agreement, GlaxoSmithKline had marketing rights to grepafloxacin in Europe, USA, and certain other markets. Otsuka retained rights for Japan and some Asian countries

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
RAXAR

Approved Use

RAXAR Tablets are Indicated for treatment of adults with mild to moderate infections caused by susceptible strains of the designated microorganisms in the infections listed below: Acute Bacterial Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. Community-acquired Pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia. Uncomplicated Gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae. Nongonococcal Urethritis and Cervicitis caused by Chlamydia trachomatis

Launch Date

1997
Curative
RAXAR

Approved Use

RAXAR Tablets are Indicated for treatment of adults with mild to moderate infections caused by susceptible strains of the designated microorganisms in the infections listed below: Acute Bacterial Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. Community-acquired Pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia. Uncomplicated Gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae. Nongonococcal Urethritis and Cervicitis caused by Chlamydia trachomatis

Launch Date

1997
Curative
RAXAR

Approved Use

RAXAR Tablets are Indicated for treatment of adults with mild to moderate infections caused by susceptible strains of the designated microorganisms in the infections listed below: Acute Bacterial Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. Community-acquired Pneumonia caused by Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, or Mycoplasma pneumonia. Uncomplicated Gonorrhea (urethral In males and endocervical and rectal in females) caused by Neissen'a gononrhoeae. Nongonococcal Urethritis and Cervicitis caused by Chlamydia trachomatis

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.43 mg/L
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.63 mg/L
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.93 mg/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.41 mg/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.26 mg/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.17 mg/L
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.47 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14.6 mg × h/L
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.2 mg × h/L
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.35 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
19.73 mg × h/L
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
27.69 mg × h/L
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
45.04 mg × h/L
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.08 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.68 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12.67 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
12.25 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.68 h
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
10.14 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
50%
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
50%
800 mg 1 times / day steady-state, oral
dose: 800 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
50%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
50%
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
50%
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
50%
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
50%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
GREPAFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 47.7 years
n = 207
Health Status: unhealthy
Condition: infections
Age Group: 47.7 years
Sex: M+F
Population Size: 207
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (3 patients)
Vomiting (1 patient)
Taste perversion (2 patients)
Dizziness (3 patients)
Diarrhea (2 patients)
Sources:
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 48.4 years
n = 204
Health Status: unhealthy
Condition: infections
Age Group: 48.4 years
Sex: M+F
Population Size: 204
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (8 patients)
Vomiting (4 patients)
Taste perversion (5 patients)
Dizziness (3 patients)
Diarrhea (1 patient)
Sources:
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 86
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (1.2%)
Vomiting (1.2%)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Disc. AE: Bad taste, Nausea...
AEs leading to
discontinuation/dose reduction:
Bad taste (0.3%)
Nausea (0.8%)
Vomiting (0.6%)
Headache (0.3%)
Dizziness (0.5%)
Rash (0.2%)
Tachycardia (<0.1%)
Sources:
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Disc. AE: Bad taste, Nausea...
AEs leading to
discontinuation/dose reduction:
Bad taste (1%)
Nausea (2.6%)
Vomiting (1.4%)
Headache (0.6%)
Dizziness (0.6%)
Rash (0.6%)
Tachycardia (0.14%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 1 patient
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 47.7 years
n = 207
Health Status: unhealthy
Condition: infections
Age Group: 47.7 years
Sex: M+F
Population Size: 207
Sources:
Diarrhea 2 patients
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 47.7 years
n = 207
Health Status: unhealthy
Condition: infections
Age Group: 47.7 years
Sex: M+F
Population Size: 207
Sources:
Taste perversion 2 patients
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 47.7 years
n = 207
Health Status: unhealthy
Condition: infections
Age Group: 47.7 years
Sex: M+F
Population Size: 207
Sources:
Dizziness 3 patients
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 47.7 years
n = 207
Health Status: unhealthy
Condition: infections
Age Group: 47.7 years
Sex: M+F
Population Size: 207
Sources:
Nausea 3 patients
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 47.7 years
n = 207
Health Status: unhealthy
Condition: infections
Age Group: 47.7 years
Sex: M+F
Population Size: 207
Sources:
Diarrhea 1 patient
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 48.4 years
n = 204
Health Status: unhealthy
Condition: infections
Age Group: 48.4 years
Sex: M+F
Population Size: 204
Sources:
Dizziness 3 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 48.4 years
n = 204
Health Status: unhealthy
Condition: infections
Age Group: 48.4 years
Sex: M+F
Population Size: 204
Sources:
Vomiting 4 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 48.4 years
n = 204
Health Status: unhealthy
Condition: infections
Age Group: 48.4 years
Sex: M+F
Population Size: 204
Sources:
Taste perversion 5 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 48.4 years
n = 204
Health Status: unhealthy
Condition: infections
Age Group: 48.4 years
Sex: M+F
Population Size: 204
Sources:
Nausea 8 patients
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 48.4 years
n = 204
Health Status: unhealthy
Condition: infections
Age Group: 48.4 years
Sex: M+F
Population Size: 204
Sources:
Nausea 1.2%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 86
Sources:
Vomiting 1.2%
Disc. AE
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 86
Sources:
Rash 0.2%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Bad taste 0.3%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Headache 0.3%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Dizziness 0.5%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Vomiting 0.6%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Nausea 0.8%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Tachycardia <0.1%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
n = 1069
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1069
Sources:
Tachycardia 0.14%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Dizziness 0.6%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Headache 0.6%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Rash 0.6%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Bad taste 1%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Vomiting 1.4%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Nausea 2.6%
Disc. AE
600 mg 1 times / day steady, oral
Recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy, adult
n = 1406
Health Status: unhealthy
Condition: lower respiratory tract infections or sexually transmitted infections
Age Group: adult
Sex: M+F
Population Size: 1406
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
[In vitro anti-MAC activities of new quinolones in focus (2)].
1996 Sep
[In vitro anti-MAC activities of new quinolones in focus (1)].
1996 Sep
Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
1999 Nov
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
2001 Mar
Fluoroquinolones as chemotherapeutics against mycobacterial infections.
2004
Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
2004 Mar
Design, synthesis and activity against Toxoplasma gondii, Plasmodium spp., and Mycobacterium tuberculosis of new 6-fluoroquinolones.
2006 Dec
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.
2010 Dec
Patents

Sample Use Guides

RAXAR (Grepafloxacin) Tablets may be taken with or without meals. The usual dose for RAXAR is 400 mg or 600 mg orally every 24 hours. Sucralfate; antacids containing magnesium, calcium, or aluminum; multivitamins containing iron or zinc; or VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 4 hours before or 4 hours after taking grepafloxacin.
Route of Administration: Oral
In Vitro Use Guide
The activity of grepafloxacin was evaluated against five isolates of Chlamydia pneumonia and 21 isolates of Chlamydia trachomatis. MICs were determined using a tissue culture incorporation technique in McCoy cell monolayers treated with Grepafloxacin. After 48–72 h incubation, cover slips were fixed in methanol and stained with an immunofluorescent monoclonal antibody against the major outer membrane protein. Grepafloxacin MIC range was 0.06–0.12 mg/L.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:56:57 GMT 2023
Edited
by admin
on Fri Dec 15 15:56:57 GMT 2023
Record UNII
A4ER1Z8N9N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GREPAFLOXACIN HYDROCHLORIDE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
GREPAFLOXACIN HCL
Common Name English
GREPAFLOXACIN HYDROCHLORIDE [MART.]
Common Name English
GREPAFLOXACIN HYDROCHLORIDE [USAN]
Common Name English
(±)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-5-METHYL-7-(3-METHYL-1-PIPERAZINYL)-4-OXO-3-QUINOLINECARBOXYLIC ACID MONOHYDROCHLORIDE
Systematic Name English
Grepafloxacin hydrochloride [WHO-DD]
Common Name English
RAXAR
Brand Name English
GREPAFLOXACIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-5-METHYL-7-(3-METHYL-1-PIPERAZINYL)-4-OXO-, MONOHYDROCHLORIDE, (±)-
Common Name English
GREPAFLOXACIN HYDROCHLORIDE [VANDF]
Common Name English
GREPAFLOXACIN HYDROCHLORIDE [MI]
Common Name English
OPC-17116
Code English
Classification Tree Code System Code
NCI_THESAURUS C795
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
Code System Code Type Description
RXCUI
236862
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY RxNorm
CAS
161967-81-3
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
SMS_ID
100000078442
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
PUBCHEM
656829
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046692
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL583
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
FDA UNII
A4ER1Z8N9N
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
MERCK INDEX
m5850
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY Merck Index
DRUG BANK
DBSALT000913
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
USAN
HH-58
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
NCI_THESAURUS
C65818
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
EVMPD
SUB14024MIG
Created by admin on Fri Dec 15 15:56:57 GMT 2023 , Edited by admin on Fri Dec 15 15:56:57 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
PARENT -> SALT/SOLVATE
SALT/SOLVATE -> PARENT
SOLVATE->ANHYDROUS
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY